In our previous study, 85 evaluable elderly patients with newly diagnosed AML were treated with decitabine in combination with granulocyte colony-stimulating factor, low-dose cytarabine and aclarubicin

No reference salvage regimen has been established in elderly patients with refractory or relapsed acute myeloid leukemia (AML). In our study, six patients older than 60 diagnosed with refractory or relapsed AML received programmed infusions of granulocyte colony-stimulating factor (G-CSF)–mobilized HLA-mismatched donor peripheral-blood stem cells after the DCAG regimen of chemotherapy treatment. The complete remission (CR) rate was 33.33% after the first therapy cycle. The median recovery times of neutrophils and platelets were 12 days and 14.5 days, respectively. No acute graft-versus-host disease (GVHD) or chronic GVHD was observed in any of the patients. The median overall survival (OS) time was 6.2 months (range, 0.9-26.2), and one out of six patients (16.7%) achieved persistent CR. In Conclusion, DCAG regimenin in combination with microtransplantation was well tolerated and showed a promising clinic efficacy in elderly patients with refractory or relapsed AML.